Pioneer Investment Management Inc. lowered its stake in Becton, Dickinson and Company (NYSE:BDX) by 17.1% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 234,216 shares of the medical instruments supplier’s stock after selling 48,421 shares during the period. Pioneer Investment Management Inc. owned 0.11% of Becton, Dickinson and worth $45,698,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. North Star Investment Management Corp. grew its position in Becton, Dickinson and by 3.4% in the 1st quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock worth $101,000 after purchasing an additional 18 shares during the last quarter. Almanack Investment Partners LLC. acquired a new stake in shares of Becton, Dickinson and in the 1st quarter worth approximately $105,000. Parkside Financial Bank & Trust lifted its stake in shares of Becton, Dickinson and by 1.4% in the 1st quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after acquiring an additional 9 shares during the period. Financial Architects Inc lifted its stake in shares of Becton, Dickinson and by 62.7% in the 1st quarter. Financial Architects Inc now owns 677 shares of the medical instruments supplier’s stock worth $124,000 after acquiring an additional 261 shares during the period. Finally, QCI Asset Management Inc. NY lifted its stake in shares of Becton, Dickinson and by 9.2% in the 1st quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock worth $130,000 after acquiring an additional 60 shares during the period. 87.42% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/09/09/becton-dickinson-and-company-bdx-shares-sold-by-pioneer-investment-management-inc.html.

BDX has been the subject of several recent research reports. BidaskClub lowered shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Bank of America Corporation restated a “buy” rating and issued a $225.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Stifel Nicolaus restated a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Zacks Investment Research lowered shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Monday, August 7th. Finally, Raymond James Financial, Inc. upgraded shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and dropped their price objective for the company from $210.00 to $180.00 in a research note on Friday, June 30th. One research analyst has rated the stock with a sell rating, five have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Becton, Dickinson and currently has an average rating of “Buy” and a consensus target price of $195.79.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at 203.70 on Friday. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63. The company has a market capitalization of $46.35 billion, a P/E ratio of 58.99 and a beta of 1.06. The company’s 50 day moving average is $200.12 and its 200 day moving average is $190.74.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.44 by $0.02. The business had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm’s revenue for the quarter was down 5.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.35 earnings per share. Analysts expect that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be issued a dividend of $0.73 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.43%. Becton, Dickinson and’s payout ratio is 83.43%.

In related news, insider Ellen R. Strahlman sold 9,283 shares of the business’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the transaction, the insider now directly owns 26,638 shares in the company, valued at $5,279,917.98. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the business’s stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the transaction, the insider now owns 12,861 shares in the company, valued at $2,538,890.01. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 48,605 shares of company stock worth $9,718,986. 1.40% of the stock is owned by corporate insiders.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.